Effectiveness of ezetimibe in improving lipid goal attainment in patients with coronary heart diseases treated with statin
10.3760/cma.j.issn.0254-6450.2009.06.023
- VernacularTitle:联合应用依折麦布对他汀治疗冠心病患者血脂达标率的影响
- Author:
Shu-Juan CHENG
1
;
Hong-Bing YAN
;
Qin MA
;
Fang-Xing XU
Author Information
1. 首都医科大学附属北京安贞医院
- Keywords:
Dislipidemia;
Ezetimibe;
Statin
- From:
Chinese Journal of Epidemiology
2009;30(6):631-632
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of ezctimibe on uncontrolled LDL-C when added to ongoing statin therapy in patients with coronary heart diseases (CHD) and diabetes mellitus (DM). Methods 61 patients with LDL-C level exceeding target goal (<2.07 mmol/L) after 12 weeks' treatment with statins, received ezetimibe in addition to their ongoing statin therapy for 8 weeks. Lipid parameters, alanine aminotransferase(ALT), aspartic aminotransferase(AST) and ereatine kinase(CK) were compared before and after the adding of ezetimibe. Results LDL-C before and after the adding of ezetimibe was (2.74±0.43) mmol/L and (2.19±0.32) mmol/L, respectively (P=0.03) in 61 patients. Ezetimibe added to statin therapy significantly reduced the LDL-C level and TC level by additional 20.1% and 19.1%, respectively (P<0.05). 74%(45/61) patients treated with ezetimibe added to statin reached their target LDL-C goal. No change of TG and HDL-C was observed and no change of AST, ALT and CK was found either. Conclusion Ezetimibe added to statin therapy lowered LDL-C level further and improved the goal attainment in patients with CHD and DM.
